Tolero Pharmaceuticals to Present Preclinical Pipeline Data at the 20th Congress of European Hematology Association, EHA

SALT LAKE CITY--()--Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced the upcoming presentations on two of their preclinical programs. TP-0903, an AXL kinase inhibitor, and TP-0184, an ALK-2 kinase inhibitor, are advancing toward first-in-human clinical trials. Preclinical findings will be presented at the 20th Congress of European Hematology Association, EHA, in Vienna Austria, from June 11 through June 14, 2015.

Details of the E-Poster presentation are as follows:

Abstract: E881
Abstract Title: Inhibition of AXL Kinase Suppresses Retinoic Acid Metabolism Through Regulation of CYP26
Topic: Acute myeloid leukemia – Biology
Date & Time: Friday, June 12, 9:30 a.m. to Saturday, June 13, 6:45 p.m. CEST
Location: E-poster screens

Details of the oral presentation are as follows:

Abstract: S501
Abstract Title: TP-0184 Lowers Hepcidin Levels and Is a Potential Therapeutic for Anemia of Chronic Disease
Topic: Red blood cells and iron - Biology
Session Title: Iron clinical and biology
Date: Saturday, June 13
Time: 3:45 p.m. - 4:00 p.m. CEST
Location: Room Stolz 2

About Tolero
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.


Tolero Pharmaceuticals, Inc.
Joe Nilson, 801-285-6003